Korsana Biosciences officer proposes 10,001-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Korsana Biosciences, Inc. (KRSA) officer and director Regina Margaret Graul filed a notice listing 10,001 common shares for sale, with an aggregate market value of $374,315.43. The notice gives November 20, 2026, as the approximate sale date and names Morgan Stanley Smith Barney LLC as broker. The shares were acquired upon vesting of restricted stock during November 7, 2019, through July 16, 2026.
Key Figures
Key Terms
Restricted Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.